DRIHEALTHCARE

ADVANCING SCIENCE

in the Fast-Growing Pharmaceutical and Biotechnology Sector

September 2023

Disclaimer

This presentation has been prepared by DRI Healthcare Trust (the "Trust"). The Trust is an unincorporated open-ended fund trust governed by the laws of the Province of Ontario, Canada and is externally managed by DRI Capital Inc. ("DRI Capital" or the "Manager" and together with the Trust, "DRI Healthcare"). The Trust completed an initial public offering (the "IPO") on February 11, 2021 in which it acquired an initial portfolio of royalty assets from DRI Capital. The predecessor of the Manager was founded in 1989. Any references to employees or historical figures prior to the IPO refer to those of the Manager.

Certain statements made in this presentation, including responses to questions, may contain forward-looking statements within the meaning of the safe harbor provisions of Canadian provincial securities laws. Forward-looking statements involve risks and uncertainties, and undue reliance should not be placed on such statements. Certain material factors or assumptions are applied in making forward-looking statements and actual results may differ materially from those expressed or implied in such statements.

Statements regarding the Trust's 2025 outlook are based on its most up-to-date view of its prospects as of the date of this presentation. This long-term outlook includes potential royalty transactions currently in the Trust's pipeline and future royalty transactions that it may bring into its pipeline in accordance with its strict investment criteria. This long-term outlook assumes no material adverse events following the date of this presentation.

For additional information about factors that may cause actual results to differ materially from expectations, and about material factors or assumptions applied in making forward-looking statements, please consult the MD&A, the Risk Factors section of the Annual Information Form and DRI Healthcare Trust's other filings with Canadian securities regulators. DRI Healthcare Trust does not undertake to update any forward-looking statements; such statements speak only as of the date made.

This presentation also makes reference to certain non-GAAP financial measures including Total Cash Receipts, Normalized Total Cash Receipts, Total Cash Royalty Receipts and Adjusted EBITDA, and certain non-GAAP ratios including Adjusted EBITDA Margin and Adjusted Cash Earnings per Unit. These measures and ratios are not standardized measures under IFRS and are therefore unlikely to be comparable to similar financial measures disclosed by other issuers. Rather, these measures and ratios are provided as additional information to complement those IFRS measures by providing further understanding of DRI Healthcare Trust's financial performance from management's perspective. Accordingly, these measures should not be considered in isolation nor as a substitute for analysis of financial information reported under IFRS.

All dollar figures in this presentation are stated in US dollars.


Low risk exposure to rapid biopharma growth

34-year¹
History
\$2.5B+
Capital deployed

74 Royalty acquisitions

6,500+ Royalty opportunities in proprietary database

DRIHEALTHCARE



For the last twelve months ended June 30, 2023

\$105M Total Income

\$90M Adjusted EBITDA²

86% Adjusted EBITDA Margin²

\$766M³ Capital deployed since IPO

Therapeutic area allocation based on net book value pro forma as at June 30, 2023

Diverse portfolio with large pharmaceutical company characteristics

- Historical data includes activities prior to establishment of DRI Healthcare Trust in February 2021
- Adjusted EBITDA is a non-GAAP measure and Adjusted EBITDA Margin is a non-GAAP ratio. See "Financial Review: Non-GAAP Financial Measures" in our MD&A, which includes a reconciliation of IFRS to non-GAAP measures. The MD&A is available on SEDAR at www.sedar.com
- 3. Excludes \$69 million in potential additional deployment in milestones

Investment Highlights





Our competitive advantages

1 Seasoned team

of specialized investment professionals with life science backgrounds and advanced business and scientific degrees

Disciplined capital allocation

based on robust investment criteria that has resulted in 22% net IRRs over three funds since 2006

3 Proactive sourcing

proprietary database tracking royalties on more than 2,000 drugs worldwide combined with deep industry relationships developed over our 30-year history

Strong execution

fundamental ground-up diligence on opportunities to execute highquality transactions






Delivering on our long-term objectives

	At IPO	Today	2025 ¹
Capital deployment	Target of \$650 – 750 million over 5 years	\$766 million deployed to date + \$69 million in potential milestones	Revised deployment target of \$850 – 900 million
Sustainable cash generation	Declining cash curve due to expected asset expiries	Mid-teens total income CAGR through 2025 and low single digit total income CAGR through 2030 excluding any new transactions	7% - 9% total income compound annual growth rate
Portfolio duration	8 years	>10 years	>10 years
Capital resources	IPO proceeds and debt capacity	Equity offering proceeds plus attractive credit facilities with compounding effect of cash flows	Expanded credit facilities with compounding effect of cash flows

Focus on building long-term and sustainable strategic growth

DRIHEALTHCARE

1. Statements regarding the Trust's 2025 outlook are based on its most up-to-date view of its prospects as of the date of this presentation. This long-term outlook includes potential royalty transactions currently in the Trust's pipeline and future royalty transactions that it may bring into its pipeline in accordance with its strict investment criteria. This long-term outlook assumes no material adverse events following the date of this presentation.



Deployment pace and need for capital by counterparties \rightarrow 5 year deployment target increased to \$850 – 900 million³


1. Includes \$24.5 million royalty acquired on July 20, 2022 and \$3.7 million royalty acquired from a separate counterparty on April 3, 2023

2. We sold our interest in Tzield on April 27, 2023 to an affiliate of Sanofi SA ("Sanofi")

DRIHEALTHCARE

3. Deployment target is consistent with historical deployment since IPO, combined with assumed future capital availability based on forecasted royalty receipts and credit capacity. Forecasted royalty receipts take into account the existing assets in our portfolio and future execution of transactions in our pipeline of opportunities at a pace consistent with our past performance.

Creating win-win deals for multiple counterparties



A proven and repeatable asset identification, selection and execution process

Proven track record of closing accretive transactions

	Investment Thesis	Transac	tion Size
⁰ ORSERDU [®]	Newly approved and first in class oncology product with uncapped growth potential	\$85 million	Up to \$140 million ¹
	High-quality oncology product with strong growth potential	Up to \$135 million ²	\$66 million ³
Tzield	Newly approved Diabetes product with long-term cash flows and growth potential		100.0 million 0.0 million
X enpozyme [™]	Only approved product for ASMD with strong IP and long duration		million + potential milestones
OMIDRIA [®]	Structured transaction on established product providing cash accretion	\$125	million
Zejula	High-quality oncology product with multiple pipeline indications		million + tential milestone
SEMPAVELI SYFOVRE	Hematology and ophthalmology product with long-term horizon and attractive growth prospects		million ⁴ + ential milestone
Oracea	Dermatology product with existing commercial track record	\$50.5	million

Completed eleven acquisitions since IPO totaling up to \$835 million, with \$766 million deployed to date

1. Represents a second royalty on Orserdu acquired from Radius Health, Inc. on August 14, 2023

DRIHEALTHCARE

Includes \$50 million secured loan made to CTI BioPharma ("CTI") on August 25, 2021, \$60 million royalty acquired from CTI on February 28, 2022 and \$6.5 million milestone payment made to CTI on January 25, 2023. On June 26, 2023, after being acquired by Swedish Orphan Biovitrum AB (Sobi), CTI repaid its loan in full and the related credit agreement was terminated.

Represents a second royalty on Vonjo acquired from S*Bio Pte Ltd on July 25, 2023

4. Includes \$24.5 million royalty acquired on July 21, 2022 and \$3.7 million royalty acquired from a separate counterparty on April 3, 2023

Orserdu royalty transactions

TRANSACTION HIGHLIGHTS

<u>Orserdu I</u> \$85 million up front purchase price Mid single digit tiered royalty on worldwide net sales

<u>Orserdu II</u>

\$130 million up front plus potential \$10 million milestone Low to high single digit tiered royalty on worldwide net sales

Royalties collected on a 1-quarter lag

STRONG GROWTH POTENTIAL

Approved by the FDA in January 2023 and currently under review by the EMA for potential approval

^OORSERDU[®]

Significant PFS benefit over SOC in ESR1m patients with limited side effects and convenience of oral administration

The Trust is also entitled to receive regulatory and sales-based milestones in addition to royalties

Uncapped royalties on long-duration asset

Vonjo II royalty transaction

TRANSACTION HIGHLIGHTS

\$66 million purchase price for tiered royalty on worldwide net sales

STRONG GROWTH POTENTIAL

First year of sales strongly exceeded analyst consensus estimates

Approved by the FDA in February 2022 as the only treatment for Myelofibrosis with severe thrombocytopenia

DRI entitled to receive up to \$107.5

million in milestone payments

VONJO

\$6.5 million payment made to CTI in January 2023 for achieving sales milestone on Vonjo I royalty

On June 6, 2023, Sobi acquired CTI for \$1.7 billion

Second royalty on Vonjo increases exposure to long duration high-quality asset

Tzield royalty transactions

ACQUISITION FROM MACROGENICS

\$100 million up front purchase price for a single digit royalty on Provention Bio's worldwide net sales

> Up to a \$50 million potential milestone tied to the successful advancement of treatment of newly diagnosed or recent-onset Type 1 diabetes by 2028

Additional \$50 million potential milestone payment based on exceeding certain sales thresholds **SALE TO SANOFI**

Sanofi announced agreement to acquire Provention Bio days after DRI Healthcare's acquisition of the royalty


> \$210 million up front sale for DRI Healthcare's royalty entitlement

Sanofi is now obligated to pay up to \$100 million in milestones

Allows for reinvesting of proceeds to generate compounding effect

Tzield

Sustainable and efficient business model focused on cashflow



Business model allows for continuous compounding of cash flows



1. Total Cash Receipts and Adjusted EBITDA are non-GAAP measures. Adjusted EBITDA Margin and Adjusted Cash Earnings per Unit is a non-GAAP ratio. See "Financial Review: Non-GAAP Financial Measures" in our MD&A, which includes a reconciliation of IFRS to non-GAAP measures. The MD&A is available on SEDAR at www.sedar.com

Q2 financial highlights






Normalized Total Cash Receipts and Adjusted EBITDA are non-GAAP measures. Adjusted EBITDA Margin and Adjusted Cash Earnings per Unit are non-GAAP ratios. See the following disclosure in "Financial Review: Non-GAAP Financial Measures" in the MD&A of DRI Healthcare Trust for Q2 2023 (the "MD&A"), consisting of the first paragraph under the subheading "Total Cash Receipts Normalized Total Cash Royalty Receipts" on page 16 of the MD&A, the reconciliation table for Total Cash Receipts, Normalized Total Cash Receipts, and Total Cash Royalty Receipts on page 17 of the MD&A and the disclosure on pages 19, 20 and 21 of the MD&A under the subheadings "Adjusted EBITDA Margin" and "Adjusted Cash Earnings Per Unit", which disclosure is incorporated by reference in this presentation. The MD&A is available on SEDAR at www.sedarplus.ca.

Strong cash generation

Adjusted EBITDA for the Last Twelve Months Ended June 30, 2023 (\$M)¹



Cash available to drive portfolio growth and maintain distributions to unitholders

TDA Margin and Adjusted Cash Farnings per Unit are non-GAAP ratios. Adjusted ERITDA Margin is calculated as Adjusted ERITDA / Normalized Total Cash Receipts. See "Financial Review" Non-G

previous the enclosed of the assets income and interest receivable at the beginning of period interest receivable at the end of period interest receivable included in the purchase price of the assets less other interest income and less prepayment premium income on loar DRIHEALTHCARE

elated to board of trustee unit-based compensation and \$0.5 million

are net of \$13.7 million non-recurring management fees related to the Tzield sale

Adjusted Cash Earnings per Unit is the sum of Adjusted Cash Earnings per Unit in each of the last four quarters, calculated as net earnings and other comprehensive earnings, plus: (i) amortization of royalty assets, (iii) amortization of other current assets, (iii) unit-based compensation, (iv) board of trustees unit-based compensation, and (v) management and performance fees on sale of royalty assets, and less; (i) non-cash royalty income. (ii) non-cash interest and other income on loan receivable. (iii) prenav on sale of royalty assets, divided by fully-diluted weighted average units outstanding

Trust units are undervalued relative to royalty peers

	Price / book	Price / operating cash flow	Dividend yield
DRIHEALTHCARE	0.9x	4.3x	9.1%
ROYALTY PHARMA	2.1x	8.3x	2.6%
XOMA	1. 5x	Neg	0.0%
Ligand	1.7x	8.0x	0.0%
Franco-Nevada	4.1x	27.1x	0.9%
WHEATON PRECIOUS METALS	2.8x	25.5x	1.4%

Valuation comps highlight Trust's underlying value



Information sourced from respective companies' Q2 2023 financial statements and share price as of September 5, 2023 DRI Healthcare cash flow calculated as Cash Flow from Operating Activities plus Cash Interest Received less Cash Interest Paid DRI Healthcare price / book ratio includes adjustment made for the follow-on offering of 9,223,000 units issued for gross proceeds of \$74 million

DHT undervalued vs. large pharmas despite favourable revenue growth, profitability and risk profile


	2022-2030 Revenue CAGR	EV / 2024 EBITDA
DRIHEALTHCARE	Low single digit	4.3x
abbvie	1.3%	12.1x
AMGEN	1.4%	9.7x
Ull Bristol Myers Squibb	-2.8%	8.5x
MERCK	1.8%	11.3x
U NOVARTIS	2.3%	11.9x
Roche	2.5%	9.6x

DHT trades at a discount relative to multiple comparable peer sets



17

Our key priorities



Invest in our people and build the industry leading royalty investment team

Execute on strong pipeline and operate at peak performance in all aspects of our business

Focus on long-term, sustainable growth generating strong unitholder returns

DRIHEALTHCARE


Contact Us

David Levine ir@drihealthcare.com

DRIHEALTHCARE


Appendix – Deal Summaries

Xenpozyme royalty transaction



Long duration product with strong IP protection anticipated to generate high multiple on invested capital

Omidria royalty transaction



Substantial near-term cash flows with long-term structural growth anticipated

Zejula royalty transaction

TRANSACTION HIGHLIGHTS

\$35 million up front purchase price

0.5% net royalty on worldwide net sales by GSK

Royalties collected on 1-quarter lag

STRONG GROWTH POTENTIAL

\$10 million milestone payment if Zejula is approved by FDA for the treatment of endometrial cancer by December 21, 2025

In development for metastatic castrate sensitive and resistant prostate cancer, endometrial cancer, HER2-breast cancer, and non-small cell lung cancer

Royalties are expected to expire in Q2 2033

Multiple indications in development represent a pipeline in a product

Zejula

Empaveli royalty transaction

TRANSACTION HIGHLIGHTS

\$28.2 million purchase price¹ plus a \$4.0 million potential milestone payment

<1% royalty on worldwide net sales up to \$500 million per annum SYFOVRE

Option to increase the annual sales cap to \$1.1 billion in return for a onetime payment of \$21 million²

STRONG GROWTH POTENTIAL

Represents a significant advancement in the standard of care for Paroxysmal Nocturnal Hemoglobinuria

Approved as the first and only approved treatment for Geographic Atrophy in February 2023

In development for pipeline indications including Cold Agglutinin Disease and C3 Glomerulopathy

Long-term horizon and attractive growth prospects

Includes \$24.5 million royalty acquired on July 20, 2022 and \$3.7 million royalty acquired from a separate counterparty on April 3, 2023
 The option expired as of June 1, 2023



Oracea royalty transaction

TRANSACTION HIGHLIGHTS

\$50.5 million purchase price for royalties on worldwide sales

Among leading treatment options for managing papulopustular rosacea

Oracea

Approved by the FDA in 2006, it has an established commercial track record

STRONG GROWTH POTENTIAL

Immediate accretive value with substantial royalty receipts netted out of purchase price

Two additional royalty interests acquired as part of transaction

Royalties collected on a 1-quarter lag and are expected to expire in Q1 2028

Strong cash flows generate immediate revenues

Deal structure case study: CTI BioPharma / Vonjo

	CTi	
Pre-approval	\$50 million secured loan	- Funding for Vonjo launch preparation - Secured loan provided downside protection if approval not granted
Upon approval	\$60 million tiered royalty	 Funding for Vonjo launch Sliding royalty rates as annual sales increase DRI obtains higher royalty on lower tranche of annual sales
Milestones by Q3 2023	Up to \$25 million	- Two potential milestones in event Vonjo sales exceed certain thresholds by Q3 2023 - Risk sharing for different launch curves

Proven ability to provide flexibility in deal structuring while managing risk